Granisetron (Kytril) plus dexamethasone for antiemetic control in bone marrow transplant patients receiving highly emetogenic chemotherapy with or without total body irradiation

Abstract

this prospective trial evaluated the efficacy and toxicity of granisetron for antiemetic control in patients receiving high-dose cyclophosphamide (cy)-containing regimens with/without tbi for bone marrow (bm) or peripheral blood stem cell (pbsc) transplantation or pbsc mobilization. granisetron 1 mg i.v. plus dexamethasone 10 mg i.v. were administered daily 30 min before chemotherapy or radiation for a median of 5 days. response was defined as the number of emetic episodes per 24 h: complete response, 0 and no emetic rescue; major response, 1–2; minor response, 3–5; failure, >5. One hundred patients were enrolled. Ninety-eight received CY-containing regimens and 26 of these additionally received TBI (12 Gy divided over 4 days). Response was complete on 216 (47%) of a total 456 patient days, major on 222 (49%), minor on 14 (3%), and failure on 4 (1%). Mean number of emetic episodes per patient per day and breakthrough medication required per patient per day was 0.24 (range 0–8) and 0.40 (range 0–8), respectively. Adverse effects were minimal, with headache (20%) reported most frequently. Based on these results, granisetron plus dexamethasone is an effective and well-tolerated antiemetic regimen in BMT/PBSCT recipients conditioned with high-dose chemotherapy with/without TBI. Bone Marrow Transplantation (2000) 25, 1279–1283.